1. Home
  2. ASLE vs OTLK Comparison

ASLE vs OTLK Comparison

Compare ASLE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerSale Corporation

ASLE

AerSale Corporation

HOLD

Current Price

$5.87

Market Cap

309.5M

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.75

Market Cap

249.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASLE
OTLK
Founded
2008
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
309.5M
249.6M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
ASLE
OTLK
Price
$5.87
$0.75
Analyst Decision
Hold
Buy
Analyst Count
2
4
Target Price
$7.00
$2.50
AVG Volume (30 Days)
382.5K
15.8M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
55.91
EPS
N/A
N/A
Revenue
$335,286,000.00
$8,146,123.00
Revenue This Year
$23.41
$1,430.98
Revenue Next Year
$6.80
$173.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.56
$0.16
52 Week High
$9.08
$3.39

Technical Indicators

Market Signals
Indicator
ASLE
OTLK
Relative Strength Index (RSI) 41.81 34.56
Support Level $5.56 $0.75
Resistance Level $6.77 $0.94
Average True Range (ATR) 0.23 0.13
MACD -0.06 -0.02
Stochastic Oscillator 26.67 10.88

Price Performance

Historical Comparison
ASLE
OTLK

About ASLE AerSale Corporation

AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: